Fineline Cube

Follow:
14422 Articles
Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas
CompanyDrug

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline
CompanyDeals

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials
CompanyDrug

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors
CompanyDrug

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
CompanyDrug

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
CompanyDeals

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
CompanyDeals

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
Policy / Regulatory

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint
CompanyDeals

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint

Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
CompanyDeals

Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology

AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform
CompanyDeals

AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection
CompanyDrug

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection